Latest Breaking News On - சுவடு குறுகிய - Page 1 : comparemela.com

Share this article Share this article DUBLIN, June 15, 2021 /PRNewswire/  Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved StrataGraft ® (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen – dsat) for the treatment of adults with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated (deep partial-thickness burns). Please see Important Safety Information for StrataGraft below. Experience the interactive Multichannel News Release here: This project was funded in part with $86 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS), under contract HHSO100201500027 for Stratatech Corporation, a Mallinckrodt company, to develop StrataGraft.

United statesSteven romanoBen ricklesDanielj specialeRon bartlettMark tyndallGary disbrowMallinckrodt pharmaceuticalsStratatech corporationRegional burn center at baton rouge generalUnited states government accountability officeBiomedical advanced researchHuman servicesCounsel government affairsUs department of healthDrug administration